A Multicenter, Prospective Clinical Study of Olverembatinib Combined With Chemotherapy in the Treatment of de Novo Adult Philadelphia Chromosome-positive Acute Lymphoid Leukemia
Latest Information Update: 05 Sep 2022
Price :
$35 *
At a glance
- Drugs Olverembatinib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 27 Aug 2022 Planned End Date changed from 31 May 2024 to 30 Sep 2024.
- 27 Aug 2022 Planned primary completion date changed from 30 Jul 2023 to 30 Sep 2023.
- 27 Aug 2022 Planned initiation date changed from 1 Aug 2022 to 1 Oct 2022.